Chan RW, Chan MC, Wong AC, Karamanska R, Dell A, H. DAS181 Inhibits H5N1 Influenza virus Infection of Human Lung Tissues. Antimicrob Agents Chemother. 2009 Jul 13
DAS181 is a novel therapeutic candidate against influenza virus which functions via the mechanism of removing the virus receptor, sialic acid (Sia) from the adjacent glycan structures. DAS181 and its analogues have previously been shown to be potently active against multiple strains of seasonal and avian influenza virus strains in several experimental models including cell lines, mice and ferrets. Here we demonstrate that DAS181 treatment leads to desialylation of both the alpha2-6-linked and alpha2-3-linked Sia in the ex vivo human lung tissue culture and primary pneumocytes. DAS181 treatment also effectively protects the human lung tissue and pneumocytes against the highly pathogenic avian influenza (HPAI) H5N1 (A/Vietnam/3046/2004). Two doses of DAS181 treatment given at 12 h apart were sufficient to block H5N1 infection in the ex vivo lung tissue culture. These findings support the potential value of DAS181 as a broad-spectrum therapeutic agent against influenza viruses, especially H5N1.
See Also:
Latest articles in those days:
- Influenza D Virus Infection in China, 2022-2023 8 hours ago
- Evidence of reassortment of avian influenza A (H2) viruses in Brazilian shorebirds 8 hours ago
- Epitopes in the HA and NA of H5 and H7 avian influenza viruses that are important for antigenic drift 2 days ago
- Assessment of CD8+ T-cell mediated immunity in an influenza A(H3N2) human challenge model in Belgium: a single centre, randomised, double-blind phase 2 study 2 days ago
- Dual N-linked glycosylation at residues 133 and 158 in the hemagglutinin are essential for the efficacy of H7N9 avian influenza virus like particle vaccine in chickens and mice 2 days ago
[Go Top] [Close Window]